Cargando…
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy. Vibecotamab (XmAb14045), a humanized bispecific antibody, monovalently...
Autores principales: | Ravandi, Farhad, Bashey, Asad, Foran, James, Stock, Wendy, Mawad, Raya, Short, Nicholas, Yilmaz, Musa, Kantarjian, Hagop, Odenike, Olatoyosi, Patel, Anand, Garcha, Raman, Ainsworth, William Barrett, Clynes, Raphael, Kanodia, Jitendra, Ding, Ying, Li, Huajiang, Kye, Steve, Mims, Alice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632668/ https://www.ncbi.nlm.nih.gov/pubmed/37647601 http://dx.doi.org/10.1182/bloodadvances.2023010956 |
Ejemplares similares
-
Acute promyelocytic leukemia current treatment algorithms
por: Yilmaz, Musa, et al.
Publicado: (2021) -
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019) -
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
por: Samra, Bachar, et al.
Publicado: (2020) -
Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia
por: Guerra, Veronica A., et al.
Publicado: (2019) -
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)